Pharmacokinetic modelling of pentoxifylline and lisofylline after oral and intravenous administration in mice

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 4, 2007, Pages 495-501

  Wyska, Elzbieta ^a   Szymura Oleksiak, Joanna ^a   Pȩkala, Elzbieta ^a   Obruśnik, Anna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; KETOCONAZOLE; LISOFYLLINE; PENTOXIFYLLINE; VERAPAMIL; DRUG DERIVATIVE; HEMATOLOGIC AGENT; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TRANSPORT; EXPERIMENTAL THERAPY; INTESTINE ABSORPTION; INTESTINE CELL; MALE; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; ANIMAL; BIOLOGICAL MODEL; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; TRANSPORT AT THE CELLULAR LEVEL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; HEMATOLOGIC AGENTS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; KETOCONAZOLE; MALE; MICE; MODELS, BIOLOGICAL; PENTOXIFYLLINE; VERAPAMIL;

EID: 34250174776     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.4.0003     Document Type: Article

References (32)

1. Achira, M., Ito, K., Suzuki, H., Sugiyama, Y. (1999) Comparative studies to determine inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1: article 18
2. Bailer, A. J. (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacoki-net. Biopharm. 16: 303-309
3. Beermann, B., Ings, R., Mansby, J., Chamberlain, J., McDonald, A. (1985) Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin. Pharmacol. Ther. 37: 25-28
4. Bursten, S. L., Federighi, D. A., Wald, J., Meengs, B., Spickler, W., Nudelman, E. (1998) Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. J. Pharmacol. Exp. Ther. 284: 337-345
5. Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., Kim, R. B. (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27: 866-871
6. De Boever, S., Baert, K., De Backer, P., Croubels, S. (2005) Pharmacokinetics and oral bioavailability of pentoxyfylhne in broiler chickens. J. Vet. Pharmacol. Ther. 28: 575-580
7. Doherty, M. M., Charman, W. N. (2002) The mucosa of small intestine. How clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet. 41: 235-253
8. Heusner, J. J., Dukes, G. E., Rollins, D. E., Tolman, K. G., Galinsky, R. E. (1987) Effect of chronically administered ketoconazole on the elimination of theophylline in man. Drug Intell. Clin. Pharm. 21: 514-517
9. Hinze, H. J. (1972) Zur pharmakokinetik von 3,7-dimethyl-1-(5-oxo-hexyl)- xanthin (BL 191) am menschen. Arzneim. Forsch. 22: 1492-1495
10. Lauterbach, R., Pawlik, D., Kowalczyk, D., Ksyciński, W., Helwich, E., Zembala, M. (1999) Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit. Care Med. 27: 807-814
11. Lee, S. H., Slattery, J. T. (1997) Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab. Dispos. 25: 1354-1358
12. Levetown, M. (2002) Lisofylline: anti-acute respiratory distress syndrome or just anti-inflammatory? Crit. Care Med. 30: 246-247
13. Lillibridge, J. A., Kalhorn, T. F., Slattery, J. T. (1996) Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab. Dispos. 24: 1174-1179
14. Lin, H. L. (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 55: 53-81
15. List, A. F., Maziarz, R., Stiff, P., Jansen, J., Liesveld, J., Andrews, F., Schuster, M., Wolff, S., Litzow, M., Karanes, C., Dahlberg, S., Kirkhart, B., Bianco, J. A., Singer, J. W. (2000) A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The lisofyl-line marrow transplant study group. Bone Marrow Transplant. 25: 283-291
16. Luke, D. R., Rocci, M. L., Hoholick, C. (1986) Inhibition of pentoxifylline clearance by cimetidine. J. Pharm. Sci. 75: 155-157
17. Margolin, K., Atkins, M., Sparano, J., Sosman, J., Weiss, G., Lotze, M., Doroshow, J., Mier, J., O'Boyle, K., Fisher, R., Campbell, E., Rubin, J., Federighi, D., Bursten, S. (1997) Prospective, randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin-2 therapy in advanced renal cancer and malignant melanoma. Clin. Cancer Res. 3: 565-572
18. Marsella, R., Nicklin, C. F., Munson, J. W., Roberts, S. M. (2000) Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration. Am. J. Vet. Res. 61: 631-637
19. Miller, K., Louie, A., Baltch, A. L., Smith, R. P., Davis, P. J., Gordon, M. A. (1998) Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans. Antimicrob. Agents Chemother. 42: 2405-2409
20. Murphy, E., Hannon, D., Callaghan, B. (1987) Ketoconazole-theophylline interaction. Ir. Med. J. 80: 123-124
21. Nicklasson, M., Bjorkman, S., Roth, B., Jonsson, M., Hoglund, P. (2002) Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 14: 643-652
22. Pang, K. S. (2003) Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes. Drug Metab. Rev. 31: 1507-1519
23. Peterson, T. C., Peterson, M. R., Wornell, P. A., Blanchard, M. G., Gonzalez, F. J. (2004) Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction. Biochem. Pharmacol. 68: 395-402
24. Raju, P. I., Tolman, K. C., Davis, P. J., Ludden, T. M., Roy, T. K., Johnson, F. E. (1993) Distribution and metabolism of pentoxifylline in non-tumor-bearing mice. J. Med. 24: 353-368
25. Rice, G. C., Brown, P. A., Nelson, R. J., Bianco, J. A., Singer, J. W., Bursten, S. (1994) Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc. Natl Acad. Sci. 91: 3857-3861
26. Smith, R. V., Waller, E. S., Doluisio, J. T., Bauza, M. T., Puri, S. K., Ho, I., Lassman, H. B. (1986) Pharmacokinetics of orally administered pentoxifylline in humans. J. Pharm. Sci. 75: 47-52
27. von Moltke, L. L., Greenblatt, D. J., Duan, S. X., Schmider, J., Kudchadker, L., Fogelman, S. M., Harmatz, J. S., Shader, R. I. (1996) Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology 128: 398-407
28. Wahllander, A., Paumgartner, G. (1989) Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur. J. Clin. Pharmacol. 37: 279-283
29. Wyska, E., Pekala, E., Szymura-Oleksiak, J. (2006) Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. Chirality 18: 644-651
30. Yang, Z., Chen, M., Nadler, J. L. (2005) Lisofylline: a potential lead for the treatment of diabetes. Biochem. Pharm. 69: 1-5
31. Zeni, F., Pain, P., Vindimian, M., Gay, J. P., Gery, P., Bertrand, M., Page, Y., Page, D., Vermesch, R., Bertrand, J. C. (1996) Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit. Care Med. 24: 207-214
32. Zhang, Y., Benet, L. Z. (2001) The gut as a barrier to drug absorption. Combined role of cytochrome P450 3A and P-glycopotein. Clin. Pharmacokinet. 41: 235-253